Trends in Parasitology Spotlights Sanaria’s In Vitro Paper Published in Nature

"The whole-sporozoite-based vaccine approach has been limited by the difficulty of mass production of infectious sporozoites from infected mosquitoes. Eappen et al. describe a method for producing a large quantity of sporozoites in vitro, which opens new areas of investigations in sporozoite biology and large-scale sporozoite production for vaccine development."

Employees of the Month: Asha Patil and Yonas Abebe

The Sanaria employees of the month for December 2022 are Asha Patil and Yonas Abebe. Asha is a member of the Gametocyte team and was nominated for employee of the month for her leadership and management efforts and results. Yonas is also a member of the Gametocyte team and was nominated for employee of the month for his leadership and management of our Pharmaceutical Operations.

A randomized controlled trial showing safety and efficacy of a whole sporozoite vaccine against endemic malaria

Published in Science Translational Medicine - A highly effective malaria vaccine remains elusive despite decades of research. Plasmodium falciparum sporozoite vaccine (PfSPZ Vaccine), a metabolically active, nonreplicating, whole parasite vaccine demonstrated safety and vaccine efficacy (VE) against endemic P. falciparum for 6 months in Malian adults receiving a five-dose regimen.

Employees of the Month: Mei-Chun Chen and Ramon Dizon Jr.

The Sanaria employees of the month for October 2023 are Mei-Chun Chen and Ramon Dizon Jr.. Mei is a member of the clinical team at Sanaria and was nominated for employee of the month for her immeasurable contributions to the success of Sanaria. Ramon is a member of the Materials Management team and was nominated for employee of the month for performing his duties competently, expeditiously and with a smile, always pleasant, always willing to help and always joy to work with.

Sanaria and Seattle Children’s Research Institute host the first live i-PfSPZ-C meeting since 2019 in Seattle, WA, USA

From November 3rd-4th, 2022, Sanaria and Seattle Children's Research Institute hosted 289 researchers from 86 institutions from 28 countries in person and virtually at the International (i) - Plasmodium falciparum (PfSPZ) - Consortium (C) meeting to further a collaborative approach for presentation of data and setting research and clinical development strategies for PfSPZ based vaccines and products.

Sanaria collaborators at Seattle Children’s Research Institute report on safety and efficacy of early arresting, non-replicating, genetically attenuated malaria sporozoite vaccine.

In a publication in Science Translational Medicine, Sean Murphy, Stefan Kappe and colleagues at Seattle Children’s Research Institute (SCRI) report the safety and efficacy against controlled human malaria infection of the administration by mosquito bite of Plasmodium falciparum (Pf) parasites attenuated by deletion of three genes. 

COLLABORATORS PUBLISH ARTICLE IN NATURE COMMUNICATIONS: PLASMODIUM FALCIPARUM 7G8 CHALLENGE PROVIDES CONSERVATIVE PREDICTION OF EFFICACY OF PFNF54-BASED PFSPZ VACCINE IN AFRICA

ROCKVILLE, MD, USA – July 12, 2022 – Sanaria Inc., University of Maryland School of Medicine, Naval Medical Research Center, National Institutes of Health (USA), University of Bamako Malaria Research and Training Center (Mali), and University of Tübingen (Germany) published results in Nature Communications showing Plasmodium falciparum 7G8 human challenge trials provide a conservative prediction of efficacy of PfNF54-based PfSPZ Vaccine in Africa.

Prince Ned Nwoko Foundation Visits Sanaria

On Tuesday, June 21st 2022, Sanaria was pleased to welcome Prince Ned Nwoko (virtually) and Mr. Chuks Anyaduba to Sanaria to discuss future interactions.  Sanaria looks forward to a long a fruitful partnership as we push together towards our shared goal of a PfSPZ vaccine that will help to eliminate malaria.

Please see link for Prince Ned Nwoko Foundation’s press release on this visit.|

Sanaria Announces the Start of Clinical Trials of its PfSPZ Vaccines in Mali and Indonesia

Sanaria Inc. announces that two new Phase 2 trials of its pioneering malaria vaccines have started.  The first is in 6- to 10-year-old children living in Bancoumana, Mali, a malarious region of West Africa. The second is in Indonesian soldiers based in Sumatra, Indonesia. The soldiers will be deploying for six to nine months this coming August to an intensely malarious district in eastern Indonesia.

Employee of the Month: Urvashi Rai

The Sanaria employee of the month for May, 2022 is Urvashi Rai. Urvashi is a member of the Vaccine Extraction and Model Systems team and was nominated for employee of the month for her outstanding efforts to create, train, and maintain an exclusive taskforce at Sanaria called the "Part-time Vaccine extraction specialists."

Contact Us


We welcome your feedback and inquiries. Please be in touch.

Address:

Sanaria Inc.
9610 Medical Center Drive, Suite 200
Rockville, MD 20850

Phone:

+1.301.770.3222

Social: